Dr Elliot Goldstein from ProMIS Neurosciences with Zacks Small Cap Research

This week, John Vandermosten, Zacks’ Senior Biotech Analyst, speaks with CEO of ProMIS Neurosciences, Dr. Elliot Goldstein on CEO Money. ProMIS’ ticker is PMN on the Toronto Exchange and ARFXF here in the US. ProMIS is focused on finding a cure for Alzheimer’s and other neurodegenerative diseases.

Dr Elliot Goldstein
President and CEO
PROmis Neurosciences
ProMIS™ Neurosciences, Inc., headquartered in Toronto Ontario, and with offices in Cambridge Massachusetts, is publicly traded on the TSX (ticker symbol: PMN.TO). As a development stage biotech company ProMIS’ mission is the discovery and development of best in class precision therapeutics for treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).

Elliot Goldstein brings a unique track record in the clinical, regulatory and commercial development of new pharmaceuticals. Dr. Goldstein began his career with Sandoz Pharmaceuticals (now Novartis), a fourteen-year period on drug development in France, Basel, Switzerland Global Headquarters, including as Head of Clinical R&D in the United States. He subsequently held positions as SVP of Strategic Product Development at SmithKline Beecham (now GSK), CEO of British Biotech (Oxford, UK), Chief Operating Officer and Chief Medical Officer of Maxygen, and President and CMO of a startup biotech devoted to development of biosimilar monoclonal antibodies.

See Zack’s Research report regarding ProMIS:http://scr.zacks.com/News/Press-Releases/Press-Release-Details/2018/PMNTO-In-Alzheimers-Its-the-Oligomers-that-Count/default.aspx

John Vandermosten
Senior Biotechnology Analyst
Zacks Small Cap Research